New publication - Matthew Rimmer, ‘Bioprinting Regulation: Intellectual Property, Health Law, and Biomedical Innovation’, in Andy Choi (ed.) Handbook in Tissue Reconstruction and Regeneration, Singapore: Springer, 2026, pp 1-50, https://link.springer.com/rwe/10.1007/978-981-96-7448-0_9-1 The Chapter is part of a Handbook of Tissue Reconstruction and Regeneration https://link.springer.com/referencework/10.1007/978-981-96-7448-0 Having performed this paper a number of times over the years, I am happy to publish a final, long version of this work. It is also good to acknowledge the many scholars and researchers working in this burgeoning field of bioprinting regulation. #additivemanufacturing #3dprinting #bioprinting #health #publichealth #IP #innovation #productliability #consumerrights #dataprotection #privacy
health
In June, ProPublica reported that the FDA has given more than 20 foreign factories a special pass to send drugs to the U.S. even though they were made at plants the agency had banned.
Today, we’re publishing a list of those exempted drugs.
https://www.propublica.org/article/fda-drugs-banned-foreign-factories-list?utm_source=mastodon&utm_medium=social&utm_campaign=mastodon-post
#News #FDA #Medicine #Health #Diabetes #Cancer #Depression #Anxiety #HIV